DR blindness not caused by DR

Article

Visual loss in subjects with diabetic retinopathy (DR) is caused by factors other than the disease, according to study results published in the September issue of Investigative Ophthalmology & Visual Science.

Visual loss in subjects with diabetic retinopathy (DR) is caused by factors other than the disease, according to study results published in the September issue of Investigative Ophthalmology & Visual Science.

Lohrasb Ahmadian, MD, MPH, MSc, and Robert Massof, PhD, FAAO of the Lions Vision Research and Rehabilitation Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, US conducted a retrospective study assessing reading, mobility, visual motor and visual information processing. For each of these metrics, the researchers monitored the results from DR patients (n=114) and case-matched them with those of patients suffering from other ocular diseases (n=114) who were of an equivalent age (19–90 years; mean, 67.5), visual acuity (VA; mean, 0.7 logMAR), gender and general health.

After adjusting for multiple comparisons, the researchers found no statistically significant difference in any of the four metrics for the matched pairs. There was, moreover, no statistically significant difference between matched pairs when comparing two further parameters: goal-level vision-related functional ability and total visual ability.

The researchers concluded that the disease process itself is not the root cause of visual impairment in DR subjects, and that it is more likely that the visual impairment that these patients experience is caused by the impact of the disease in their daily lives.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.